RxDoctor Payments Data

Jessica Bradley

Nurse Practitioner · Milford, DENPI 1578037784

Payments from drug & device makers

$1,713in general payments, 2019–2025

Across 22 payments — averaging $77.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$929
  • Medtronic$332
  • Sumitomo Pharma America, Inc.$191
  • Astellas Pharma US Inc$89
  • Seagen Inc.$85
  • Tolmar Pharmaceuticals, Inc.$24
  • plus $63 from 3 others

What the payments were for

  • Food & beverage$1,53990%
  • Education$17410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,713 in reported general payments places this provider in the 80th percentile of 487 nurse practitioner providers in Delaware.

See all nurse practitioner providers in Delaware

Medicare billing

Part B allowed, 2024
$160,257
Medicare patients
605
Services billed
4,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide60$822,875
XtandiEnzalutamide39$456,334
OrgovyxRelugolix84$225,308
MyrbetriqMirabegron167$196,478
GemtesaVibegron84$92,607
FirmagonDegarelix Acetate11$16,487
Tamsulosin Hcl736$14,475
Silodosin67$7,706
Finasteride322$6,198
PremarinEstrogens, Conjugated11$5,221
Estradiol39$2,532
Trospium Chloride30$2,270
Potassium Citrate ErPotassium Citrate17$2,140
Methenamine Hippurate19$2,019
Alfuzosin Hcl ErAlfuzosin Hcl71$1,660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$929$822,87560 claims
Astellas Pharma US IncXtandi, Myrbetriq$89$652,812206 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$191$317,916168 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 487 nurse practitioner providers in Delaware.

Other nurse practitioner in Milford

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →